EUFOREA consensus on biologics for CRSwNP with or without asthma

被引：270

作者：

Fokkens, Wytske J. ^{[1
,2
]}

Lund, Valerie ^{[3
]}

Bachert, Claus ^{[2
,4
,5
,6
]}

Mullol, Joaquim ^{[7
]}

Bjermer, Leif ^{[8
]}

Bousquet, Jean ^{[2
,9
]}

Canonica, Giorgio W. ^{[10
,11
]}

Deneyer, Lauren ^{[2
]}

Desrosiers, Martin ^{[12
]}

Diamant, Zuzana ^{[8
,13
,14
,15
,16
,17
]}

Han, Joseph ^{[18
]}

Heffler, Enrico ^{[10
,11
]}

Hopkins, Claire ^{[19
]}

Jankowski, Roger ^{[20
]}

Joos, Guy ^{[21
]}

Knill, Andrew ^{[22
]}

Lee, Jivianne ^{[23
]}

Lee, Stella E. ^{[24
]}

Marien, Gert ^{[2
]}

Pugin, Benoit ^{[2
,25
]}

Senior, Brent ^{[26
]}

Seys, Sven F. ^{[2
,25
]}

Hellings, Peter W. ^{[1
,2
,25
,27
]}

机构：

[1] Amsterdam Univ Med Ctr, Dept Otorhinolaryngol, Locat AMC Amsterdam, Amsterdam, Netherlands

[2] European Forum Res & Educ Allergy & Airway Dis EU, Brussels, Belgium

[3] Univ Coll London Hosp, Royal Natl Throat Nose & Ear Hosp, London, England

[4] Univ Ghent, Upper Airways Res Lab, Ghent, Belgium

[5] Karolinska Univ Hosp, Karolinska Inst, CLINTEC, Div ENT Dis, Stockholm, Sweden

[6] Karolinska Univ Hosp, Dept ENT Dis, Stockholm, Sweden

[7] Univ Barcelona, Hosp Clin, Dept Otorhinolaryngol, CIBERES,IDIBAPS, Barcelona, Catalonia, Spain

[8] Lund Univ, Dept Resp Med & Allergol, Lund, Sweden

[9] Univ Hosp Arnaud de Villeneuve, Dept Resp Dis, Montpellier, France

[10] IRCCS, Personalized Med Asthma & Allergy Humanitas Clin, Rozzano, MI, Italy

[11] Humanitas Univ, Dept Biomed Sci, Pieve Emanuele, MI, Italy

[12] Univ Montreal Hosp Ctr CHUM, Div Otolaryngol Head & Neck Surg, Montreal, PQ, Canada

[13] Univ Med Ctr Groningen, Dept Clin Pharm & Pharmacol, Groningen, Netherlands

[14] Univ Med Ctr Groningen, Dept Gen Practice, Groningen, Netherlands

[15] QPS NL, Groningen, Netherlands

[16] Charles Univ Prague, Fac Med 1, Dept Resp Med, Prague, Czech Republic

[17] Thomayer Hosp, Prague, Czech Republic

[18] Eastern Virginia Med Sch, Dept Otolaryngol Head & Neck Surg, Norfolk, VA 23501 USA

[19] Guys & St Thomas NHS Fdn Trust, London, England

[20] Univ Hosp Nancy, ENT Dept, Brabois ILM, Nancy, France

[21] Ghent Univ Hosp, Dept Resp Med, Ghent, Belgium

[22] Opuscomms, London, England

[23] Univ Calif Los Angeles, Dept Head & Neck Surg, Rhinol & Endoscop Skull Base Surg, Los Angeles, CA USA

[24] Univ Pittsburgh, Sch Med, Dept Otolaryngol Head & Neck Surg, Div Sinonasal Disorders & Allergy, Pittsburgh, PA 15261 USA

[25] Dept Microbiol Immunol & Transplantat, Allergy & Clin Immunol Res Grp, Leuven, Belgium

[26] Univ North Carolina Chapel Hill, Div Rhinol Allergy & Endoscop Skull Base Surg, Chapel Hill, NC USA

[27] Univ Hosp Leuven, Dept Otorhinolaryngol Head & Neck Surg, Leuven, Belgium

来源：

ALLERGY | 2019年 / 74卷 / 12期

关键词：

asthma; biologics; chronic rhinosinusitis; nasal polyps; type; 2; inflammation; ENDOSCOPIC SINUS SURGERY; ADULT CHRONIC RHINOSINUSITIS; NATIONAL COMPARATIVE AUDIT; QUALITY-OF-LIFE; NASAL POLYPOSIS; OMALIZUMAB; PREVALENCE; MANAGEMENT; ALLERGY; CORTICOSTEROIDS;

D O I：

10.1111/all.13875

中图分类号：

R392 [医学免疫学];

学科分类号：

100102 ;

摘要：

Novel therapies such as type 2 targeting biologics are emerging treatment options for patients with chronic inflammatory respiratory diseases, fulfilling the needs of severely uncontrolled patients. The majority of patients with chronic rhinosinusitis with nasal polyps (CRSwNP) and over half of patients with asthma show a type 2 inflammatory signature in sinonasal mucosa and/or lungs. Importantly, both chronic respiratory diseases are frequent comorbidities, ensuring alleviation of both upper and lower airway pathology by systemic biological therapy. Type 2-targeting biologics such as anti-IgE, anti-IL4R alpha, anti-IL5, and anti-IL5R alpha have entered the market for selected pheno/endotypes of asthma patients and may soon also become available for CRSwNP patients. Given the high prevalence of chronic respiratory diseases and the high cost associated with biologics, patient selection is crucial in order to implement such therapies into chronic respiratory disease care pathways. The European Forum for Research and Education in Allergy and Airway Diseases (EUFOREA) organized a multidisciplinary Expert Board Meeting to discuss the positioning of biologics into the care pathways for CRSwNP patients with and without comorbid asthma.

引用

页码：2312 / 2319

页数：8

共 77 条

[1] Efficacy of omalizumab 150 mg/month as a maintenance dose in patients with severe chronic spontaneous urticaria showing a prompt and complete response to the drug
Asero, Riccardo
[J]. ALLERGY, 2018, 73 (11) : 2242 - 2244
[2] Endotype-driven care pathways in patients with chronic rhinosinusitis
Bachert, Claus
Zhang, Nan
Hellings, Peter W.
Bousquet, Jean
[J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2018, 141 (05) : 1543 - 1551
[3] Effect of Subcutaneous Dupilumab on Nasal Polyp Burden in Patients With Chronic Sinusitis and Nasal Polyposis A Randomized Clinical Trial
Bachert, Claus
Mannent, Leda
Naclerio, Robert M.
Mullol, Joaquim
Ferguson, Berrylin J.
Gevaert, Philippe
Hellings, Peter
Jiao, Lixia
Wang, Lin
Evans, Robert R.
Pirozzi, Gianluca
Graham, Neil M.
Swanson, Brian
Hamilton, Jennifer D.
Radin, Allen
Gandhi, Namita A.
Stahl, Neil
Yancopoulos, George D.
Sutherland, E. Rand
[J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2016, 315 (05): : 469 - 479
[4] Reduced need for surgery in severe nasal polyposis with mepolizumab: Randomized trial
Bachert, Claus
Sousa, Ana R.
Lund, Valerie J.
Scadding, Glenis K.
Gevaert, Philippe
Nasser, Shuaib
Durham, Stephen R.
Cornet, Marjolein E.
Kariyawasam, Harsha H.
Gilbert, Jane
Austin, Daren
Maxwell, Aoife C.
Marshall, Richard P.
Fokkens, Wytske J.
[J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2017, 140 (04) : 1024 - +
[5] Current and future treatment options for adult chronic rhinosinusitis: Focus on nasal polyposis
Bachert, Claus
Zhang, Luo
Gevaert, Phillippe
[J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2015, 136 (06) : 1431 - 1440
[6] Bidder T, 2018, RHINOLOGY, V56, P42, DOI [10.4193/Rhin17.139, 10.4193/Rhino17.139]
[7] Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial
Blauvelt, Andrew
de Bruin-Weller, Marjolein
Gooderham, Melinda
Cather, Jennifer C.
Weisman, Jamie
Pariser, David
Simpson, Eric L.
Papp, Kim A.
Hong, H. Chih-Ho
Rubel, Diana
Foley, Peter
Prens, Errol
Griffiths, Christopher E. M.
Etoh, Takafumi
Pinto, Pedro Herranz
Pujol, Ramon M.
Szepietowski, Jacek C.
Ettler, Karel
Kemeny, Lajos
Zhu, Xiaoping
Akinlade, Bolanle
Hultsch, Thomas
Mastey, Vera
Gadkari, Abhijit
Eckert, Laurent
Amin, Nikhil
Graham, Neil M. H.
Pirozzi, Gianluca
Stahl, Neil
Yancopoulos, George D.
Shumel, Brad
[J]. LANCET, 2017, 389 (10086) : 2287 - 2303
[8] Anti-immunoglobulin E (omalizumab) therapy in allergic asthma
Busse, WW
[J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2001, 164 (08) : S12 - S17
[9] Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma
Castro, M.
Corren, J.
Pavord, I. D.
Maspero, J.
Wenzel, S.
Rabe, K. F.
Busse, W. W.
Ford, L.
Sher, L.
FitzGerald, J. M.
Katelaris, C.
Tohda, Y.
Zhang, B.
Staudinger, H.
Pirozzi, G.
Amin, N.
Ruddy, M.
Akinlade, B.
Khan, A.
Chao, J.
Martincova, R.
Graham, N. M. H.
Hamilton, J. D.
Swanson, B. N.
Stahl, N.
Yancopoulos, G. D.
Teper, A.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (26) : 2486 - 2496
[10] International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma
Chung, Kian Fan
Wenzel, Sally E.
Brozek, Jan L.
Bush, Andrew
Castro, Mario
Sterk, Peter J.
Adcock, Ian M.
Bateman, Eric D.
Bel, Elisabeth H.
Bleecker, Eugene R.
Boulet, Louis-Philippe
Brightling, Christopher
Chanez, Pascal
Dahlen, Sven-Erik
Djukanovic, Ratko
Frey, Urs
Gaga, Mina
Gibson, Peter
Hamid, Qutayba
Jajour, Nizar N.
Mauad, Thais
Sorkness, Ronald L.
Teague, W. Gerald
[J]. EUROPEAN RESPIRATORY JOURNAL, 2014, 43 (02) : 343 - 373

← 1 2 3 4 5 6 7 8 →